Probiotic-drug co-delivery system enhances sulfasalazine activation for inflammatory bowel disease therapy

spore (CBs) with chitosan (CS) and Eudragit S100 (EudS-100). After oral administration, it is identified that the CS and EudS-100 coating enables the colonic release of SSZ. On the one hand, CBs germinates into CB, which facilitates the conversion of SSZ to 5-ASA, relieving inflammation and repairing intestinal barrier. On the other hand, CB modulates the disordered gut microbiota. This provides a new strategy for integrating probiotic therapy with pharmacological treatment in the management of IBD.